Progress of treatment of Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2016.12.003
- VernacularTitle:霍奇金淋巴瘤治疗研究进展
- Author:
Xiaohui ZHOU
;
Jianyong LI
;
Wei XU
- Keywords:
Hodgkin lymphoma;
American Society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(12):714-716
- CountryChina
- Language:Chinese
-
Abstract:
Hodgkin lymphoma (HL) is a highly curable malignancy for most patients. Frontline treatment is generally ABVD alone or combination with other chemotherapy regimens or radiation. However, the treatment of relapsed refractory HL (RR HL) remains a major challenge for clinicians. High dose chemotherapy followed by autologous stem cell transplantation is the preferred treatment for chemoresistant patients. In addition, the combination of brentuximab vedotin (BV) with programmed cell death receptor 1 monoclonal antibody nivolumab, BV combined with ICE (ifosfamide, carboplatin, etoposide), panobinotast in combination with ICE and many other new drugs are in clinical trials and research. The latest progress in treatment of HL is reported in depth in the 58th American Society of Hematology Annual Meeting.
